About Us

Pioneers in Solid Tumor Cell Therapy

The Tmod™ technology was invented by A2 Bio scientists, leveraging decades of experience across several disciplines of drug discovery science. A2 Bio’s approach is highly integrative and draws heavily from quantitative drug discovery methods pioneered outside the cell therapy field. The Tmod™ technology affords A2 Bio a first-mover advantage to revolutionize the treatment of solid tumors by exploiting the loss of genetic material commonly seen in tumors. We are protecting our technology and planned pipeline products with a broad and deep set of patent filings.

The Tmod™ technology was invented by A2 Bio scientists

We are driven by a commitment to rigorous science and the urgency to bring cell therapies to cancer patients. Led by an experienced leadership team, equipped with versatile research and manufacturing infrastructure, supported by a world-class scientific advisory board and powered by a team of dedicated scientists and professional staff, A2 Bio is uniquely positioned to deliver a broad pipeline of T cell therapies to cancer patients.

A2 Bio Timeline

  • January 2018

    A2 Bio founded. Company raises $57M in Series A financing

  • September 2018

    A2 Bio establishes new research facility in Agoura Hills, CA

  • May 2019

    Scott Foraker, JD, appointed president and CEO

  • March 2020

    Manufacturing facility established

  • August 2020

    Publishing of first manuscript in a peer reviewed journal

  • October 2020

    Company closes $71.5M Series B financing

  • December 2020

    First pre-clinical data demonstrating the potential for the Tmod™ platform in oncology published in 𝘔𝘰𝘭𝘦𝘤𝘶𝘭𝘢𝘳 𝘐𝘮𝘮𝘶𝘯𝘰𝘭𝘰𝘨𝘺

  • December 2020

    Company enters into collaboration with Merck to develop allogeneic cell therapy for solid tumor cancers

  • December 2020

    Company enters a strategic collaboration with Tempus to develop a companion diagnostic (CDx) test for A2 Bio’s new therapy targeting patients with loss of heterozygosity (LOH)

  • May 2021

    Thomas Leung appointed as CFO

  • June 2021

    Clinical candidates for autologous carcinoembryonic antigen+ (CEA) and mesothelin+ (MSLN) cancers nominated

  • August 2021

    cGMP manufacturing facility operational

  • September 2021

    Clinical candidate nominated for 1st allogeneic program

  • October 2021

    Company raises $75M in Series B extension

  • November 2021

    First BASECAMP-1 site opened at New York University (NYU) Langone Health

  • January 2022

    Poster presented at American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium on use of next-generation sequencing to identify patients for future CAR T therapy

  • June 2022

    A2 Bio signs lease for phase 2 manufacturing facility in Agoura Hills, CA

  • August 2022

    Companion diagnostic developed with Tempus cleared by the FDA

  • October 2022

    A2 Bio receives “Future of Agoura Hills” – Business of the Year award

  • November 2022

    Clinical candidate nominated for 2nd allogeneic program

  • November 2022

    Company closes $62M Series B extension financing

  • January 2023

    FDA clearance for the CEA IND

  • May 2023

    First patient dosed in EVEREST-1 Phase 1 trial of A2B530 (CEA program)